178 related articles for article (PubMed ID: 38370384)
21. Human aldo-keto reductases 1B1 and 1B10: a comparative study on their enzyme activity toward electrophilic carbonyl compounds.
Shen Y; Zhong L; Johnson S; Cao D
Chem Biol Interact; 2011 May; 191(1-3):192-8. PubMed ID: 21329684
[TBL] [Abstract][Full Text] [Related]
22. Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers.
Matsunaga T; Wada Y; Endo S; Soda M; El-Kabbani O; Hara A
Front Pharmacol; 2012; 3():5. PubMed ID: 22319498
[TBL] [Abstract][Full Text] [Related]
23. AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer.
Hojnik M; Šuster NK; Smrkolj Š; Sisinger D; Grazio SF; Verdenik I; Rižner TL
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159076
[TBL] [Abstract][Full Text] [Related]
24. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
[TBL] [Abstract][Full Text] [Related]
25. AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis.
Ohashi T; Idogawa M; Sasaki Y; Suzuki H; Tokino T
Mol Cancer Res; 2013 Dec; 11(12):1554-63. PubMed ID: 24140838
[TBL] [Abstract][Full Text] [Related]
26. Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10.
Morikawa Y; Kezuka C; Endo S; Ikari A; Soda M; Yamamura K; Toyooka N; El-Kabbani O; Hara A; Matsunaga T
Chem Biol Interact; 2015 Mar; 230():30-9. PubMed ID: 25686905
[TBL] [Abstract][Full Text] [Related]
27. AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas.
Hojnik M; Frković Grazio S; Verdenik I; Rižner TL
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298614
[TBL] [Abstract][Full Text] [Related]
28. Statil suppresses cancer cell growth and proliferation by the inhibition of tumor marker AKR1B10.
Cao Z; Zhou B; Chen X; Huang D; Zhang X; Wang Z; Huang H; Wang Y; Cao D
Anticancer Drugs; 2014 Sep; 25(8):930-7. PubMed ID: 24800887
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
He YC; Shen Y; Cao Y; Tang FQ; Tian DF; Huang CF; Tao H; Zhou FL; Zhang B; Song L; He L; Lin LM; Lu FG; Liao DF; Cao D
Cancer Biomark; 2016; 16(1):127-35. PubMed ID: 26835713
[TBL] [Abstract][Full Text] [Related]
30. Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
Zhang W; Li H; Yang Y; Liao J; Yang GY
Cancer Lett; 2014 Dec; 355(2):273-80. PubMed ID: 25304374
[TBL] [Abstract][Full Text] [Related]
31. Perspective on the Structural Basis for Human Aldo-Keto Reductase 1B10 Inhibition.
Ruiz FX; Parés X; Farrés J
Metabolites; 2021 Dec; 11(12):. PubMed ID: 34940623
[TBL] [Abstract][Full Text] [Related]
32. Impaired Barrier Function and Immunity in the Colon of Aldo-Keto Reductase 1B8 Deficient Mice.
Wang X; Khoshaba R; Shen Y; Cao Y; Lin M; Zhu Y; Cao Z; Liao DF; Cao D
Front Cell Dev Biol; 2021; 9():632805. PubMed ID: 33644071
[TBL] [Abstract][Full Text] [Related]
33. [Expression of aldo-keto reductase family 1 member B10 in gastric cancer tissues and its clinical significance].
Yao HB; Xu Y; Chen LG; Guan TP; Ma YY; Tao HQ; Shao QS
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Feb; 16(2):183-7. PubMed ID: 23446484
[TBL] [Abstract][Full Text] [Related]
34. AKR1B10, a good prognostic indicator in gastric cancer.
Yao HB; Xu Y; Chen LG; Guan TP; Ma YY; He XJ; Xia YJ; Tao HQ; Shao QS
Eur J Surg Oncol; 2014 Mar; 40(3):318-24. PubMed ID: 24406159
[TBL] [Abstract][Full Text] [Related]
35. Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Loeffler-Ragg J; Mueller D; Gamerith G; Auer T; Skvortsov S; Sarg B; Skvortsova I; Schmitz KJ; Martin HJ; Krugmann J; Alakus H; Maser E; Menzel J; Hilbe W; Lindner H; Schmid KW; Zwierzina H
Mol Cancer Ther; 2009 Jul; 8(7):1995-2006. PubMed ID: 19567817
[TBL] [Abstract][Full Text] [Related]
36. Regulation of aldo-keto-reductase family 1 B10 by 14-3-3ε and their prognostic impact of hepatocellular carcinoma.
Liu TA; Jan YJ; Ko BS; Wu YJ; Lu YJ; Liang SM; Liu CC; Chen SC; Wang J; Shyue SK; Liou JY
Oncotarget; 2015 Nov; 6(36):38967-82. PubMed ID: 26516929
[TBL] [Abstract][Full Text] [Related]
37. Regulation of aldo-keto reductase AKR1B10 gene expression: involvement of transcription factor Nrf2.
Nishinaka T; Miura T; Okumura M; Nakao F; Nakamura H; Terada T
Chem Biol Interact; 2011 May; 191(1-3):185-91. PubMed ID: 21277289
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers: A meta-analysis.
Liu R; Zheng S; Yang CY; Yu Y; Peng S; Ge Q; Lin Q; Li Q; Shi W; Shao Y
Medicine (Baltimore); 2021 Apr; 100(14):e25454. PubMed ID: 33832153
[TBL] [Abstract][Full Text] [Related]
39. Exposure to 9,10-phenanthrenequinone accelerates malignant progression of lung cancer cells through up-regulation of aldo-keto reductase 1B10.
Matsunaga T; Morikawa Y; Haga M; Endo S; Soda M; Yamamura K; El-Kabbani O; Tajima K; Ikari A; Hara A
Toxicol Appl Pharmacol; 2014 Jul; 278(2):180-9. PubMed ID: 24813866
[TBL] [Abstract][Full Text] [Related]
40. AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
Schmitz KJ; Sotiropoulos GC; Baba HA; Schmid KW; Müller D; Paul A; Auer T; Gamerith G; Loeffler-Ragg J
Liver Int; 2011 Jul; 31(6):810-6. PubMed ID: 21645211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
